The Edinburgh Cancer Discovery Unit (ECDU) and Edinburgh University have sealed a deal this week with the American drugs Giant Eli Lilly to develop new drugs in the fight against cancer. The ECDU will be providing expertise and cutting edge biological techniques to help Lilly identify which of its chemical compounds may be effective as anti-cancer therapies.
Neil Carragher , Principal Investigator of the ECDU and Edinburgh Cancer Research Centre said “The collaboration provides an excellent opportunity to partner the latest innovations in cancer research from the ECDU with compounds from Lilly’s oncology pipeline.”
For the full story please see the Scotsman website:
£3.5m Grant paves way for medical centre: July 2010
2010 Queen's Birthday Honours for MRC Scientist: June 2010
Screening test hope for bone disease: 2 May 2010
New fellows: The Royal Society of Edinburgh:5 March 2010
A functional edge 2010: 11 February 2010
Elected to EMBO: 22 October 2009
Osteoporosis and coeliac disease: 9 October 2009
Gala awards for innovators:19 August 2009
Major investment genetics and genomics research:
2 June 2009
Genetic Clues Key to Schizophrenia Treatment: 9 March 2009
The Future Of Cancer Treatment: Can We Afford It?: March 2009
IGMM Workshop: February 2009
Scientist's quest to ease Bone Patients: 16 February 2009
Elected 2010 Balfour Lecturer: 5 February 2009
Untangling the String: 5 February 2009
Study sheds light on cause of Bowel Disease:
10 December 2008
Study sheds light on cause of bowel disease: 10 December 2008
IGMM Communications Group: December 2008
IGMM Retreat: 15 October 2008
PhD Student Award: 1 October 2008
Royal Society Awards: August 2008
Breast Cancer World Class Research Unit: 4 June 2008Genetics of Inflammatory Bowel Disease: 14 May 2008
Racial Differences in Response to Bowel Cancer Genetic Risk Factor: 1 April 2008
Osteoporosis Research Investigating Effects of Cannabis Drug on Thinning Bones: 26 March 2008
New Support for DISC1: 13 March 2008
Award Winning Images of Science: 12 Mar 2008
Gene Could Spell New Chapter in Fight Against Gout: 10 Mar 08
New Fellows: The Royal Society of Edinburgh
7 Mar 08
MRC Centre in Cognitive Ageing and Cognitive Epidemiology: 5 Mar 2008
Dr Matt Cockerill: 7 Feb 08
Professor Sir Ian Wilmut: 24 Jan 08
The outstanding work of IGMM researchers is regularly recognised both within the Institute and by external bodies.
Professor David Porteous FRSE, Director of The Centre for Genomic and Experimental Medicine and Professor of Human Genetics and Molecular Medicine at The University of Edinburgh, was awarded an OBE for Services to Science in the New Years Honours List 2013.
Congratulations to Professor Porteous and all of the IGMM researchers who have received a promotion or award recently (some of which are highlighted below), they are a great recognition of your hard work and dedication to science.
We are delighted to congratulate Val Brunton (ECRC, IGMM) on her promotion to Personal Chair, Andrew Jackson (HGU, IGMM) on his promotion to Professorial Fellow and Pleasantine Mill (HGU, IGMM) or her promotion to a Programme Leader Track position.
These promotions are very well deserved and great recognition of the outstanding contribution each make to their science.
Andrew Jackson was also elected to EMBO membership in May in recognition of research excellence and outstanding achievements in the life sciences.
Juan-Carlos Acosta received a prestigious CR-UK Career Development Fellowship in May, recognising him as an outstanding scientist at the start of his independent career. The award commences in October to study the “Characterization of the Senescence Associated Extracellular Matrix (SA-ECM) and its role in cancer progression”.
Kyle Francis won The Pathological Society Sir Alastair Currie Poster Prize in June for his “checkpoint kinase 1 as a poor prognostic ovarian cancer biomarker” poster at the Edinburgh Pathology 2013 Meeting.
Juan Lopez-Baez won a poster prize in July at the 8th International Zebrafish Conference in Barcelona. There were more than 450 posters and over 850 participants, so this is a great achievement highlighting the importance of his work into the discovery of a novel notochord damage response.
Girish Mali won a prize for best presentation at the Molecular Genetics of Development Workshop at the Institute of Child Health in November.
The human face is strongly genetically determined and as distinctive as a fingerprint. Unless you are an identical twin, no one else looks exactly like you. But what is it in our genetic make-up that allows humanity to create such a huge diversity of face shape?
A recent study led by Axel Visel at Berkeley Lab and co-authored by David FitzPatrick and Harris Morrison from our MRC Human Genetics Unit, has shown that differences in the activity of gene enhancers – regions of DNA that regulate gene function – drive subtle variation in facial development. This suggest that our face shape is be due to the unique cocktail of these enhancers that we inherit from our parents.
High-resolution 3D videos produced by Harris using Optical Projection Tomography – an imaging technique developed in the MRC Human Genetics Unit - accompany the “Fine Tuning of Craniofacial Morphology by Distant-Acting Enhancers” paper in the journal Science and highlight the enhancer regions involved in facial development in mice.
Watch the Video: Harris Morrison, MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh
It is hoped that further research into these enhancer regions will ultimately lead to the improved diagnosis and treatment of facial birth defects.